Metastasis is the leading cause of cancer-related deaths; metastatic lesions develop from disseminated cancer cells (DCCs) that can remain dormant1. Metastasis-initiating cells are thought to originate from a subpopulation present in progressed, invasive tumours2. However, DCCs detected in patients before the manifestation of breast-cancer metastasis contain fewer genetic abnormalities than primary tumours or than DCCs from patients with metastases3,4,5. These findings, and those in pancreatic cancer6 and melanoma7 models, indicate that dissemination might occur during the early stages of tumour evolution3,8,9. However, the mechanisms that might allow early disseminated cancer cells (eDCCs) to complete all steps of metastasis are unknown8. Here we show that, in early lesions in mice and before any apparent primary tumour masses are detected, there is a sub-population of Her2+p-p38lop-Atf2loTwist1hiE-cadlo early cancer cells that is invasive and can spread to target organs. Intra-vital imaging and organoid studies of early lesions showed that Her2+ eDCC precursors invaded locally, intravasated and lodged in target organs. Her2+ eDCCs activated a Wnt-dependent epithelial–mesenchymal transition (EMT)-like dissemination program but without complete loss of the epithelial phenotype, which was reversed by Her2 or Wnt inhibition. Notably, although the majority of eDCCs were Twist1hiE-cadlo and dormant, they eventually initiated metastasis. Our work identifies a mechanism for early dissemination in which Her2 aberrantly activates a program similar to mammary ductal branching that generates eDCCs that are capable of forming metastasis after a dormancy phase.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Sosa, M. S., Bragado, P. & Aguirre-Ghiso, J. A. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat. Rev. Cancer 14, 611–622 (2014)
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011)
Schardt, J. A. et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8, 227–239 (2005)
Klein, C. A. et al. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc. Natl Acad. Sci. USA 96, 4494–4499 (1999)
Schmidt-Kittler, O. et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA 100, 7737–7742 (2003)
Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349–361 (2012)
Eyles, J. et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 120, 2030–2039 (2010)
Hüsemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58–68 (2008)
Sänger, N. et al. Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int. J. Cancer 129, 2522–2526 (2011)
Wen, H. C. et al. p38α signaling induces anoikis and lumen formation during mammary morphogenesis. Sci. Signal. 4, ra34 (2011)
Cardiff, R. D. Validity of mouse mammary tumour models for human breast cancer: comparative pathology. Microsc. Res. Tech. 52, 224–230 (2001)
Lu, J. et al. 14-3-3ζ cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial–mesenchymal transition. Cancer Cell 16, 195–207 (2009)
Strippoli, R. et al. p38 maintains E-cadherin expression by modulating TAK1-NF-κB during epithelial-to-mesenchymal transition. J. Cell Sci. 123, 4321–4331 (2010)
Entenberg, D. et al. Setup and use of a two-laser multiphoton microscope for multichannel intravital fluorescence imaging. Nat. Protocols 6, 1500–1520 (2011)
Malladi, S. et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165, 45–60 (2016)
Leung, J. Y. et al. Activation of AXIN2 expression by β-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J. Biol. Chem . 277, 21657–21665 (2002)
Grumolato, L. et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 24, 2517–2530 (2010)
Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. Emt: 2016. Cell 166, 21–45 (2016)
Bragado, P. et al. TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling. Nat. Cell Biol. 15, 1351–1361 (2013)
Brisken, C. et al. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev. 14, 650–654 (2000)
Rhim, A. D. et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology 146, 647–651 (2014)
Ocaña, O. H. et al. Metastatic colonization requires the repression of the epithelial–mesenchymal transition inducer Prrx1. Cancer Cell 22, 709–724 (2012)
Brabletz, T. To differentiate or not – routes towards metastasis. Nat. Rev. Cancer 12, 425–436 (2012)
Schmidt, J. M. et al. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Reports 10, 131–139 (2015)
Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472–476 (2015)
Hui, L. et al. p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway. Nat. Genet. 39, 741–749 (2007)
Gozdecka, M. et al. JNK suppresses tumor formation via a gene-expression program mediated by ATF2. Cell Reports 9, 1361–1374 (2014)
Bhoumik, A. et al. Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc. Natl Acad. Sci. USA 105, 1674–1679 (2008)
Fizazi, K. et al. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals Oncol. 26, v133–v138 (2015)
Narod, S. A., Iqbal, J., Giannakeas, V., Sopik, V. & Sun, P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 1, 888–896 (2015)
Hosseini, H. et al. Early dissemination seeds metastasis in breast cancer. Nature http://dx.doi.org/10.1038/nature20785 (2016)
Debnath, J., Muthuswarmy, S. K. & Brugge, J. S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 3, 256–268 (2013)
Debnath, J. & Brugge, J. S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 5, 675–688 (2015)
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012)
Thévenaz, P., Ruttimann, U. E. & Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Trans. Image Process. 7, 27–41 (1998)
We thank R. Parsons and P. Polulikakos for PI3K and AKT inhibitors, S. Aaronson and H.-C. Wen for WNT3A, SFRP1 and DKK1 reagents and expertise. Grant support:. HHMI (R.J.D.). SWCRF (J.A.A.-G. and E.F.F.), CA109182, CA196521 (J.A.A.-G.), CA163131 (J.A.A-G and J.C.), CA100324 (J.C), F31CA183185 (K.H.), BC132674 (J.A.A.-G and J.C.), BC112380 (M.S.S.). NIH 1S10RR024745. Microscopy CoRE at ISMMS. DFG KL 1233/10-1 and the ERC (322602) (C.A.K.).
J.A.A.-G. receives funding from E. Lilly and co. Jo.C. is a consultant for, and has equity in MetaStat, Inc.; and is a consultant for Deciphera Pharmaceuticals.
Nature thanks M. Bissell, C. Ghajar and the other anonymous reviewer(s) for their contribution to the peer review of this work.
Extended data figures and tables
a, Cartoons depicting the three MMTV–Her2 models used in this study and the different time frames for early lesions (EL) and overt primary tumour (PT) development. HP, hyperplasia; MIN, mammary intraepithelial neoplasia. b, Haematoxylin and eosin staining for sections of normal FVB mouse mammary tissue, and FVB MMTV–Her2 early lesions or primary tumours. c, Whole mounts from mammary glands of FVB MMTV–Her2 mice at the time early lesions were studied. LN, lymph node. d, Representative images of E-cadhip-ATF2hi (left and inset) and E-cadlop-ATF2lo (right) ducts in the MMTV–Her2-T model. Scale bar, 10 μm. Arrow in left image, intact E-cadherin junction; arrow in right image, dismantled E-cadherin junction. e, Quantification of the percentage of E-cadhi cells per duct that showed high or low p-ATF2 expression in MMTV–Her2 and MMTV–Her2-T models. *P < 0.01; one-sided, unpaired t-test; mean ± s.e.m. (Her2, n = 30 ducts; Her2-T, n = 10 ducts).
a, Early stage MMTV–Her2-T (BALB-NeuT 15 weeks of age) early lesion sections stained for Her2 and β-catenin. Arrows, Her2+β-catMEM-lo early lesion cells; arrowheads, Her2−β-catMEM-hi cells. Scale bars, 10 μm. The digital dye separation module (Leica) was used on the images. Graph, quantification of the percentage of cells per duct with β-catMEM for both MMTV–Her2 and MMTV–Her2-T models. (n = 7 ducts). b, Immunohistochemistry for p-ATF2 and E-cadherin in MMTV–Her2 early lesion tissues (age, 14–18 weeks) and primary tumour sections. Boxed regions are magnified in the bottom right panel. Note the loss of both p-ATF2 and E-cadherin in primary tumour samples. Scale bar, 25 μm. c, Western blot for the indicated antigens in lysates of mammary epithelial cells isolated from normal mammary glands (FVB) and tumour cells isolated from MMTV–Her2 overt primary tumours (Her2). GAPDH was used as a loading control. For gel source data, see Supplementary Fig. 1. d, Immunohistochemistry for p-p38 in normal epithelium (BALB/c), early lesion tissues (BALB-NeuT early lesions, 7 weeks) and overt primary tumours (BALB-NeuT primary tumours). Graph, percentage of p-p38 positive cells in each stage. n = 11–15 ducts, 5 tumours. Scale bars, 20 μm (inset) and 50 μm; **P < 0.01; ***P < 0.0001; one-tailed Mann–Whitney U-test. e, Representative images of parallel sections from DCIS patient samples stained for p-ATF2 (red), Her2 (green in insets lower row), or E-cadherin (green in large panels and insets upper row). Samples were Her2-positive (n = 5) or -negative (n = 5) by immunofluorescence microscopy analysis for Her2 (insets top and bottom row left, green). Inset right column, detail of E-cadherin junctions in Her2+ and Her2− samples. Arrowhead, strong E-cadherin junctions; arrow, weak E-cadherin staining. Scale bars, 25 μm and 10 μm (inset). f, Metamorph software was used to quantify Her2, E-cadherin and p-ATF2 fluorescence signal intensity in 10 DCIS samples shown in panel e. Mean fluorescence intensity (m.f.i.) ± s.e.m. per cell per field from Her2+ (black bars, n = 5) compared to Her2− (grey bars, n = 5) samples from patients with DCIS. ***P < 0.05; two-way ANOVA. g, Immunohistochemistry for p-p38α and p-ATF2 performed on invasive breast cancer (IBC) tumours from patients (n = 20). Samples were classified as Her2+ (n = 10) or Her2− (n = 10) by the pathology service. Note the significant reduction in both p-p38α and p-ATF2 in Her2+ tumours. Insets show additional patient samples for each group. Graph, metamorph was used to determine the mean signal intensity ± s.e.m. per field for p-p38 and p-ATF2. p-p38 intensity, left axis and first two columns of the graph. p-ATF2 intensity, right axis and last two columns of the graph. **P < 0.05; unpaired t-test. Scale bars, 25 μm.
Extended Data Figure 3 Characterization of invasive and signalling properties of Her2+ early lesions.
a, MCF10A-HER2 organoids stained for E-cadherin (green) and DAPI (blue). Left, a representative organoid. Scale bar, 25 μm. Right, details of invading E-cadlo cells (top and bottom). Arrowheads, outward invading E-cadlo cells. Scale bar, 10 μm. Approximately 35–40% of MCF10A-HER2 organoids show outward invasion of one cell per organoid in equatorial sections; 92 ± 8.3% of those invading cells are E-cadlo. b, MCF10A-HER2 organoids were stained for F-actin (red) and DAPI (blue). Note the extensions of F-actin from invading cells (boxed areas and right top and bottom insets) still in contact with the organoid. Scale bars, 20 μm. c, Detection of E-cadherin and p-ATF2 in MCF10A-HER2 cells treated with or without lapatinib (100 nM), AG1478 (5 μM) and siRNA targeting HER2 (40 nM) for 24 h; E-cadherin (green), pATF2 (red). Graph, fold change of the percentage of p-ATF2+ cells. Data are mean ± s.e.m.; **P < 0.01; ***P < 0.001; one-sided, unpaired t-test; n = 3 experimental replicates, 10 images per treatment. d, MCF10A-Her2 cells were treated for 24 h with AG1478 (1 μM) left, or with the AKT inhibitor MK2266 (5 μM), pan-PI3K inhibitor GDC-0941 (1 μM) or lapatinib (1 μM), right. Western blots for p-AKT and total AKT (T-AKT) (left) or p-S6 and β-tubulin (right). Gel source data in Supplementary Fig. 1. Graph, control for Her2 knockdown in MCF10A-HER2 cells; one-sided, unpaired t-test; median and range are shown. e, MMTV–Her2 early lesion organoids were treated with GDC-0941 (1 μM), lapatinib (1 μM) or MK2266 (5 μM) for 24 h. Organoids were fixed and stained for p-ATF2. Graph, percentage of p-ATF2+ cells per organoid. Scale bars, 25 μm. Median ± s.e.m.; one-sided, unpaired t-test. f, Left, quantification of the percentage of nuclear p-ATF2+ MCF10A-HER2 cells treated for 24 h with vehicle (CRTL), 5 μM SB203580 (SB), 100 nM lapatinib (LAP) or the combination of the two drugs. Right, representative immunofluorescence images of the p-ATF2 signal (red); DAPI (blue) was used to count total cell numbers. Insets and arrows show a detail of nuclear p-ATF2 levels in the respective groups. One-sided Mann–Whitney U-test at 95% confidence; median and range are shown, n = 2 independent wells per condition; n > 150 cells scored per condition. Scale bars, 25 μm. g, MCF10A-HER2 organoids treated for 6 days with SB203580 or DMSO and stained for F-actin (red). Bottom left graph, percentage ± s.e.m. of MCF10A-HER2 organoids with outward invasion (DMSO n = 109; SB203580 n = 87) ***P < 0.001; one-sided, unpaired t-test. Scale bars, 10 μm. Bottom right graph, percentage of invasive MMTV–Her2 organoids (DMSO n = 11; SB203580 n = 9). P = 0.01; one-sided, unpaired t-test; mean ± s.d. Representative of 3 biological replicates. h, MMTV–Her2 early lesion sections (age, 14–18 weeks) stained for CK8/18 (red), Her2 (green) and nuclei (DAPI, blue). Top image, a duct is outlined. The boxed region and bottom images showCK8/18+ and Her2+ singlets or doublets within the stroma near ducts. Graph, percentage of stroma-invading cells that were either double positive for both CK8/18 and Her2 or single CK8/18+. Mean ± s.e.m.; **P < 0.01; one-sided Mann–Whitney U-test; n = 4 mice, 60–80 cells per mouse. Scale bars, 10 μm.
a, MMTV–Her2–NDL5–CFP early lesion mammary gland tissues (seven-week-old females) co-stained for CFP (green) and Her2 (red). Arrows, co-distribution of Her2 and CFP. Graph, percentage of positive cells for the single Her2 staining (white bars) or double co-staining for Her2 and CFP (black bars) per field. Approximately 88% of early lesion cells are positive for Her2 and CFP. Scale bars, 10 μm. b, Early circulating cancer cells (eCCCs) were detected in cytospin preparations by staining for CK8/18 (green) and nuclei with DAPI (blue) after a Ficoll gradient and negative selection (see Methods). Scale bar, 10 μm. c, Detection of eDCCs in lung sections from MMTV–Her2 mice by immunohistochemistry for Her2 (rabbit anti-Her2 antibody (Abcam, ab2428)). Scale bar, 25 μm. Right, augmented images from additional sections. Red arrowheads, Her2-positive DTCs; red asterix, host Her2-negative cells. Scale bars, 10 μm. Staining controls are shown in e. d, eDCCs in the bone marrow of MMTV–Her2 mice detected in cytospin preparations of whole bone-marrow samples after a Ficoll gradient and staining for CK8/18 (green), Her2 (red) and DAPI (blue). CK8/18+, Her2+ or double-positive cells were considered eDCCs. Right, individual channel signals. Left, merged channels on the right detecting a bone-marrow CK8/18+Her2+ DCC (arrow) next to a CK8/18−Her2− bone-marrow cell (asterix). Scale bars, 10 μm. e, Top, Immunohistochemistry for Her2 in non-transgenic FVB lung sections. Her2+ cells were undetectable in FVB lung sections. Bottom, IgG isotype for the Her2 antibody used in c in lungs of MMTV–Her2 mice. Scale bars, 50 μm. f, g, Top, IgG control images for eDCC detection in MMTV–Her2 lung sections. Bottom, example of Her2+ (red) staining using the Calbiochem (OP15L) (f) and Abcam (ab2428) (g) anti-Her2 antibodies. M, mouse; R, rabbit. Scale bars, 10 μm. h, eCCCs detected by CK8/18+ as in b in blood of MMTV–Her2 mice (age, 14–18 w) treated for 2 weeks with DMSO (C) or the p38α/β inhibitor SB203580 (DMSO n = 4; SB n = 5 mice). i, eDCCs detected by CK8/18+ as in d in bone marrow of MMTV–Her2 mice treated as in h (n = 5 mice per group). j, eDCCs detected in the lung of MMTV–Her2 mice carrying only early lesions as in c and treated as in h. Graph, percentage of Her2+ eDCCs per field in each group (n = 30 fields, 3 mice per treatment). For h–j, median and individual fields (j) or mice (h, i); *P < 0.05; ***P < 0.001; one-sided Mann–Whitney U-test.
a, MCF10A-HER2 organoids treated for 6 days with SB203580 or control (DMSO) were stained for E-cadherin (green) and β-catenin (red) or DAPI (blue); MCF10A-HER2, n = 20 organoids per treatment. Scale bars, 10 μm (top), 20 μm (bottom). b, MCF10A-HER2 organoids treated with siRNAs targeting p38a or a non-targeting control (siCTL); n = 20 organoids per treatment. Scale bars, 10 μm (top), 20 μm (bottom). c, Quantification of a and b. *P < 0.048; NS, not significant; one-sided, unpaired t-test. d, Graph, percentage ± s.e.m. β-cateninMEM in MCF10A-HER2 with/without SB203580 and with/without p38a siRNA. *P = 0.0047; one-sided, unpaired t-test. e, MMTV–Her2 organoids treated with p38a or control siRNA (48 h) and stained to detect active β-catenin (see Methods). Graph, percentage ± s.e.m. of organoids stained for active β-catenin (n = 10 organoids per treatment). Scale bars, 25 μm. P = 0.0059; one-sided, unpaired t-test. f, AXIN2 mRNA expression in MCF10A-HER2 cultures treated for 24 h with DMSO control (C) or SB203580 (5 μM). Technical triplicate determinations were normalized to GAPDH and fold change (FC) over control was determined for five biological replicates. P < 0.05; one-sided, unpaired t-test, mean ± s.e.m. g, mRNA levels for SNAI1 and TWIST1 normalized to GAPDH in MCF10A-HER2 3D cultures treated with siRNA targeting the p38α isoform or ATF2 from day 6–12. Graph, fold change over control in three biological replicates. **P < 0.01; ***P < 0.0001; one-sided, unpaired t-test; mean ± s.e.m. h, Sections of MMTV–Her2 early lesions in mice treated for 2 weeks with SB203580 (see Methods) stained for E-cadherin (top) and β-catenin (bottom). Scale bars, 15 μm. Arrows, membrane E-cadherin, or β-catenin (bottom left) or nuclear β-catenin (bottom right). Boxed area is shown in Fig. 3c. i, Isotype-matched mouse IgG control immunohistochemistry for β-catenin and E-cadherin in mammary intraepithelial neoplasia and a primary tumour. Scale bars, 25 μm. j, E-cadherin immunohistochemistry in C57BL/6 (WT) and Mkk3−/− Mkk6+/− mice10 or FVB mice treated with SB203580 (see Methods). k, Quantification of j. Mean ± s.e.m.; *P < 0.01; one-sided, unpaired t-test. l, MCF10A organoids were treated for 6 days with control (DMSO) or SB203580 (5 μM), and fixed and stained for E-cadherin (green). Graph, percentage of E-cadhi organoids in two experiments; 15 organoids per treatment per trial. Scale bars, 10 μm. Mean ± s.e.m.; *P < 0.01; one-sided, unpaired t-test. m, Top, immunofluorescence for β-catenin (red) on mammary gland sections of DMSO- or SB203580-treated FVB mice(see Methods). Scale bars, 25 μm. Bottom, immunofluorescence for α-smooth muscle actin (SMA, red), CK8/18 (green) and DAPI (blue) on the same tissues. Scale bars, 20 μm.
a, qPCR confirmation of EMT genes identified in Fig. 3g comparing MCF10A and MCF10A-HER2 organoids. Mean ± s.e.m. shown as fold change over control. Values normalized to GAPDH from triplicate samples. *P < 0.05; one-sided, unpaired t-test. b, qPCR confirmation of genes identified in Fig. 3g in MCF10A-HER2 organoids treated with DMSO or SB203580. Mean ± s.e.m. shown as fold change over control. Values normalized to GAPDH from triplicate samples. *P < 0.05; one-sided, unpaired t-test. c, qPCR for CDH1 mRNA in MCF10A-HER2 organoids treated for 6 days with SB203580 (5 μM) or p38a siRNA (20 nM). Fold change over control for biological triplicates. DMSO, control for SB203580 and scrambled siRNA, control for p38a siRNA. Mean ± s.e.m.; *P < 0.05; one-sided, unpaired t-test. d, Western blot for haemagglutinin (HA)-tagged SFRP1 constructs in MCF10A-HER2-SFRP1 cell lines. Gel source data, see Supplementary Fig. 1. e, Axin2 mRNA levels in MCF10A-HER2 and MCF10A-HER2-SFRP1 cells treated with or without SB203580 (5 μM) for 24 h. Fold change over control; error bars denote s.e.m. for biological sextuplicates. *P < 0.05; one-sided, unpaired t-test. f, Axin2 mRNA levels measured in MCF10A cultures transfected with pcDNA3 (empty vector) or CA-p38α (D176A and F372S mutant) plasmids and then treated with or without WNT3A for 24 h. Fold change over control is shown; error bars denote s.e.m. for biological triplicates. *P < 0.02; one-sided, unpaired t-test. g, Percentage of outward-invading cells from MCF10A-HER2 and MCF10A-HER2-SFRP1 organoids treated for 6 days with DMSO or SB203580 (5 μM). n = 20 organoids per treatment, biological duplicates; data are shown as mean ± s.e.m.; *P < 0.05; one-sided, unpaired t-test. h, Left, E-cadherin (green) in MCF10A-HER2 and MCF10A-HER2-SFRP1 organoids treated for 6 days with SB203580 (5 μM). Right, β-catenin (red) in organoids treated as on the left. Insets (h1–h4) show magnified boxed regions. Graph, percentage of E-cadhi (green bars, left axis) and β-cateninMEM (red bars, right axis) organoids. Error bars denote s.e.m.; NS, not significant; *P < 0.003; **P < 0.02; one-sided, unpaired t-test; n = 20 organoids per treatment, biological duplicates. Scale bars, 10 μm. i, Quantification of early-lesion or primary-tumour cancer cells with the indicated profiles; 4 animals per group. **P < 0.01; one-sided Mann–Whitney U-test; mean ± s.e.m. Bottom, immunofluorescence for Twist1hi (T+) protein in HER2+ (H+) cancer cells in early lesions (n = 883 cells) or primary tumours (n ≥ 3,000 cells). j, Immunofluorescence for p-H3 (green) and Her2 (red) in eDCCs from MMTV–Her2 lung sections. Scale bars, 10 μm. k, Immunofluorescence for Her2 (red) and p-Rb (green) in spontaneous primary MMTV–Her2 tumours. Scale bar, 10 μm. l, Representative image of Her2+Twist1+ lung DCCs from 33-week-old MMTV–Neu mice. n = 500 cells, 4 animals per group. Quantification shown in Fig. 4f. Scale bar, 10 μm. m, Percentage of Her2+ and p-Rb+ cells per field of view (FOV) in MMTV–Her2 mice treated as in Fig. 3c. Lungs sections from 3 animals. *P < 0.02; ***P < 0.0001; one-sided, unpaired t-test; error bars represent ± s.e.m.
a, Experimental approach for testing tumorigenic and metastatic potential. Early lesions cells from mouse mammary glands (age, 12–18 weeks) and primary tumour cells were seeded in mammosphere medium (see representative images). Approximately 300 mammospheres were injected into the fat pad of nude mice. Primary tumour formation and metastasis was monitored for 1, 3 and 12 months (mammospheres group) or for 3 months (tumourspheres group). Primary tumour and metastasis incidence are shown in Fig. 4g. b, Sphere-forming efficiency for early lesion cancer cells (age, 16 weeks) and primary tumour cancer cells. After one week (1) in culture, spheres were disaggregated and replated to test self-renewal capacity for another week (2). n = 6 replicates; one-sided, unpaired t-test; data are mean ±s.d. Representative of 3 biological replicates. c, Left, haematoxylin and eosin staining of lung macro-metastasis in nude mice injected with MMTV–Her2 early lesion mammospheres. Scale bar, 200 μm. Right, immunohistochemistry for Her2+ DCCs in mice injected with tumourspheres. Scale bar, 10 μm. Arrows, Her2+ DCCs; asterisks, Her2− cells. d, Left, immunofluorescence detection of p-ERK1/2 and p-S6 in organoids produced by MMTV–Her2 early lesion or primary tumour cells. Right, percentage of p-S6 or p-ERK+ organoids per well. n = triplicates; one-sided, unpaired t-test; mean ± s.e.m. e, Mammosphere from early lesion cells or tumourspheres from primary tumour cells were directly embedded in 3D Matrigel to monitor organoid behaviour for 3 days. Top, percentage of invasive organoids in each group. EL, early lesion; PT, primary tumour. Bottom, representative images used to quantify the invasive nature of early lesion mammospheres (left) compared to primary tumour tumourspheres (right). P < 0.0021; one-sided, unpaired t-test; mean ± s.e.m. f, Early lesion and primary tumour single-cell suspensions were injected intravenously (tail vein) in nude mice (50,000 cells per animal). Lungs were collected (after 4 weeks) and processed for haematoxylin and eosin, and immunofluorescence for Her2 detection (right). Graph, number of metastatic nodules per section per animal lung (n = 3 mice in each group). NS, not significant; Mann–Whitney U-test; median and range are shown.
Extended Data Figure 8 Final tumour volume of early lesions or primary spheres after orthotopic injection into nude mouse mammary fat pads.
Animals were randomized and approximately 300 spheres from early lesions or primary tumours were injected per site into nude mice (BALB/cnu/nu, Charles River) with Matrigel (Corning 356231) at a 1:1 ratio. Spheres were injected into the both fourth inguinal gland fat pads using a 27-gauge needle. In the case of mice injected with tumour-derived spheres, mice were euthanized when tumours reached 1,000 mm3, according to IAUCU regulations. Tumour volumes were measured at 3 months. Mammospheres, n = 15 animals, tumourspheres, n = 13 animals. One-sided Mann–Whitney U-test with 95% confidence intervals.
Extended Data Figure 9 Cartoon depicting the mechanism of early dissemination by Her2+ early lesion cells.
a, Early Her2+ early lesion cancer cells (red) turn on Wnt, PI3K and AKT signalling, inhibit p38 activation and E-cadherin-junction formation allowing for a Twist1hi EMT-like invasive program; p38 and E-cadherin inhibit the Wnt- and β-catenin-driven EMT-like program and invasion (grey inhibitory symbols). b, Her2+p-p38loTwist1hiE-cadlo early lesion cancer cells, which retain CK8/18 expression can intravasate and disseminate. c, In lungs more than 85% of eDCCs (red) were Her2+E-cadlo(p-Rb or p-H3)lo, suggesting a large population of dormant cells. Most eDCCs are also Twist1hiE-cadlo. Nevertheless, eDCCs can initiate metastasis, which correlated with the acquisition of a Twist1loE-cadmed–hi phenotype. In the bone marrow, eDCCs were Her2+CK8/18+ and remain dormant for the duration of the experiments, as bone lesions were never observed.
This file contains the raw data for Extended Data Figures 2c, 3d, 6d. (PDF 10499 kb)
Two independent MMTV-Her2 organoids cultured for 4 days in Matrigel were imaged for 2 hours and frames were collected every 20 minutes. Top row shows the differential interference contrast (DIC) images of the two organoids with cell movement and microinvading cells toward the bottom of the field of view. The bottom row shows a variance filter from Image J software that highlights the cell edges and allows having a bright view of the microinvading cells from the organoids into the Matrigel. (MOV 792 kb)
Intra-vital imaging of mammary glands in MMTV-Her2-CFP mice was performed using a specially designed mammary gland imaging window (see Experimental Procedures for details). CFP+/Her2+ cells can be seen in the cyan/light cyan signal and vasculature was delimited using i.v. delivered dextran-rhodamine (red). Note the apparent normal duct architecture at this time, which remained organized with some intra-ductal movement observed mainly in luminal spaces. Still image of this video is shown in Figure 2a left panel. (MOV 1150 kb)
Mammary gland imaging windows were used as in Video S2 in MMTV-Her2-CFP mice at age 15 weeks when early lesions are present (Extended Data 1a-c). Motile single CFP+ cells were found micro-invading from lesions and are outlined in purple and green in the video. CFP+/Her2+ cells can be seen in cyan and vasculature was stained with dextran-rhodamine (Red). Note that here a greater digital zoom was used to show in detail the motile cells micro-invading from the ductal structure that occupies the lower right quadrant of the video. Still image of video is shown in Figure 2a middle panel. (MOV 275 kb)
Mammary gland imaging windows were used to image ducts of MMTV-Her2-CFP mice at age 18 weeks when early stage lesions are present. Single cells were found microinvading from the early stage ducts (upper right) as outlined in purple in the video. One single cell can be traced through the stroma between ducts. CFP+/Her2+ cells can be seen in cyan and vasculature was stained with dextran-rhodamine (red), which also revealed macrophages that capture the labeled dextran. Still images of video are shown in Figure 2a right panel. (MOV 1196 kb)
Intra-vital imaging of multiple micro-invasion events in MMTV-Her2-CFP mice treated for two weeks with SB203580
Imaging of MMTV-Her2-CFP mammary glands following treatment for two weeks with SB203580 (10mg/kg, i.p every 48hr). This video shows an early lesion and CFP+/Her2+ cells in cyan and vasculature stained with dextran-rhodamine (red). Note the luminal filling of ducts and increased movement of cells along the ductal walls into the stroma and into a low contrast vessel between the two lobules of the ductal structure. Still images are in Figure 2b. (MOV 550 kb)
Digital magnification of the region of Video S5 highlighted in a dotted line square inFigure 2b (inset b’)
Note the amoeboid like movement of these CFP+/Her2+ cells micro-invading cells breaking the lesion boundaries into the stroma. Note also that the motility seem to occur at the single cell level and not collectively. Still image of video is shown in Figure 2b’. (MOV 1880 kb)
3D rendering of the micro-invasion events in MMTV-Her2-CFP mice treated with the p38a/b inhibitor SB203580
3D reconstruction of Video S6 revealed that CFP+/Her2+ cells were entering the lumen of the blood vessel (RED) as revealed by the yellow overlap signal and suggesting active intravasating capacity as supported by the video S8 and the detection of CTCs and DTCs in Extended data 4h, i, j. Entry into the vessel lumen is marked when CFP+ and Dextran-Rhodamine (Red) signals overlap shown in yellow. Still images of video are shown in Figure 2c. (MPG 6184 kb)
Digital Magnification of an early lesion reveals a CFP+ cells entering the vasculature from the stroma in SB203580 treated mice. Left panel shows original imaging with a delineated vessel (yellow line) and the intravasating cell (purple line). Right panel shows a digital segmentation to isolate the vasculature (RED) and the intravasating eDCC precursor (CYAN) that turns yellow when the optical signals overlap. Still images of this sequence are shown in Figure 2d. (MOV 3012 kb)
About this article
Cite this article
Harper, K., Sosa, M., Entenberg, D. et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature 540, 588–592 (2016). https://doi.org/10.1038/nature20609
Nature Reviews Cancer (2020)
The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment
Seminars in Cancer Biology (2020)
Cell-intrinsic survival signals. The role of autophagy in metastatic dissemination and tumor cell dormancy
Seminars in Cancer Biology (2020)
Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma